Notice of Retraction: Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption

5th International Conference on Bioinformatics and Biomedical Engineering, iCBBE 2011

Volumn , Issue , 2011, Pages

  Yu, Dijia ^a,b   Bei, Yongyan ^a   Chen, Xiaoyan ^a   Liu, Yang ^a   Zhang, Xuenong ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b Suzhou Health College   (China)

Author keywords

Absorption enhancers; Chitosan nanoparticles; Intestinal absorption; Norcantharidin; P glycoprotein

Indexed keywords

BIOMEDICAL ENGINEERING; CHITOSAN; DRUG DOSAGE; DRUG PRODUCTS; GLYCOPROTEINS; MOLECULAR WEIGHT; NANOPARTICLES; RATE CONSTANTS; SODIUM DODECYL SULFATE; SULFUR COMPOUNDS;

ABSORPTION-ENHANCERS; CHITOSAN NANOPARTICLES; INTESTINAL ABSORPTION; NORCANTHARIDIN; P-GLYCOPROTEIN;

TARGETED DRUG DELIVERY;

EID: 79960129071     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/icbbe.2011.5780435     Document Type: TB

References (16)

1. Wang GS. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol. 1989, 26, 147-162.
2. Shan HB, Cai YC, Liu Y, Zeng WN, Chen HX, Fan BT, Liu XH, Xu ZL, Wang B, Xian L J. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A. Anticancer Drugs. 2006, 17(8), 905-911.
3. Kato Y. Onishi H., Machida Y. Biological characteristic of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Release, 2001, 70(3), 295-307.
4. Zhang W, Liu Y, Chen XY, Bei YY, Xu JY, Wang WJ, Zhang XN, Zhang Q Two modelling data analytical methods applied to optimise the preparationof norcantharidin chitosan nanoparticles. J Exp Nanosc,2010, 5(3), 271-284.
5. Wang Q, Zhang L, Hu W, Hu ZH, Bei YY, Xu JY, Wang WJ, Zhang XN, Zhang Q. Norcantharidin-associated galactosylated chitosan nanoparticles for dual hepatocyte-targeted delivery. Nanomedicine: Nanotechnology, Biology, and Medicine 2010, 6(2), 371-381.
6. Rubinstein A, Pathak YV, Kleinstern J, Reches A, Benita S. In vitro release and intestinal absorption of physostigmine salicylate from submicron emulsions. J Pharm Sci, 1991, 80(7), 643-647.
7. Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm. 2009, 71(2):310-317.
8. Wang L, Li CR, Jiang XH. In situ intestinal absorption behaviors of tanshinone IIA from its inclusion complex with hydroxypropyl-β- cyclodextrin. Biol Pharm Bull, 2007, 30, 1918-1922.
9. Li QZ. Using Weibull function to seek dissolution parameters. Chinese Journal of Hospital Pharmacy. 1991,11(1):30-31.
10. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S. Site of drug absorption after oral administration: assessment ofmembrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci, 2006, 29(3-4), 240-250.
11. De Boer AG.. Drug Absorption Enhancement: Concepts, Possibilities, Limitations and Trends. Harwood Academic Publisher GmbH, Chur, Switzerland, pp. 1994, 367-389.
12. Cano-Cebrián MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv. 2005, 2(1):9-22.
13. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci, 1998, 87(2), 164-169.
14. Khoo SM, Shackleford DM, Porter CJ, Edwards GA, Charman WN. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res. 2003, 20(9), 1460-1465.
15. Wan HJ,Tang X,Yang DL.Absorption kinetics of ofloxacin inrats in situ. Chinese Journal of Hospital Pharmacy.2005,25(7): 597-599.
16. Ji HY, Li ZZ, Sun JR. Absorption mechanisms of protein and peptide in oral administration. Shandong Pharm Ind, 2003, 22: 31-32.